Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection
Vinay Sundaram,1 Kris V Kowdley21Department of Medicine and Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, 2Liver Care Network, Swedish Medical Center, Seattle, WA, USAAbstract: Chronic hepatitis C virus (HCV) infection is one of the most common etiologies of liver-re...
Guardado en:
Autores principales: | Sundaram V, Kowdley KV |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ba5f8beb2510482eb17737c373e19364 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Decreasing racial disparity with the combination of ledipasvir–sofosbuvir for the treatment of chronic hepatitis C
por: Naylor PH, et al.
Publicado: (2017) -
Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life
por: Pol S, et al.
Publicado: (2016) -
Ombitasvir, paritaprevir, and ritonavir with peginterferon-α2a plus ribavirin in treatment-experienced patients with chronic hepatitis C virus genotype 1 infection
por: Bernstein D, et al.
Publicado: (2019) -
Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives
por: Degasperi E, et al.
Publicado: (2014) -
Impact of hepatitis C virus genotype-4 eradication following direct acting antivirals on liver stiffness measurement
por: Tag-Adeen M, et al.
Publicado: (2017)